Biotech in China Part II: Crown Bio and Nigel BeeleySubmitted by Theral Timpson on Wed, 08/10/2011 - 19:11
Podcast Sponsor: Biotix, Inc. - Free Samples
Alex Wu, CEO, Crown Bio, , Bio and Contact Info
Listen (2:52) China as a market growing rapidly
Listen (8:20) Big challenge is to change from low cost producers to innovators
Listen (10:55) What is being done to foster innovation?
Listen (3:32) Government offering resources, country more open
Nigel Beeley, CEO, Enrqi, Inc., Bio and Contact Info
Listen (1:50) CRO's doing more but not drivers of innovation
Listen (2:12) Is innovation happening?
Listen (5:25) Better IP protection and improved regulation
Listen (5:05) Sea Turtles not big risk takers or innovators
Listen (4:45) Working life in China
Listen (3:42) Quality
Listen (8:46) Working with the government
Today we present our second show in a series on the booming life science industry in China. As we mentioned in our first show, the Chinese government is investing billions in the life sciences and has plans to expand basic health coverage to the entire population by 2020. The last 10 years has seen the biotech industry in China come of age from a few CRO’s providing cost cutting advantage to thousands of life science companies struggling to tip the advantage scale from cost cutting to innovation. Is the innovation happening? We ask two guests today.
Alex Wu is the CEO of Crown Biosciences. His company is headquartered in Santa Clara, CA and has two divisions in China. Alex says that Crown Bio’s edge comes from innovation. Nigel Beeley has been working in China since some of the first CRO’s set up shop. He’s seen the business change incredibly and shares his hopes and his skepticisms about biotech in China.
See a recent article by David Ewing Duncan, China: The next biotech superpower?